A Short Exploration of Selected Sensitive CYP3A4 Substrates (Probe Drug)
Conclusion: It is concluded that midazolam shows a good response in all clinical studies because of its lesser half-life and bioavailability when compared with other probe drugs.
Source: Drug Metabolism Letters - Category: Drugs & Pharmacology Source Type: research
More News: Databases & Libraries | Drugs & Pharmacology | Herbs | Liver | Nanotechnology | Study | Urology & Nephrology